Unleash Immuno Oncolytics, a US firm focusing on the development of viral biologics in the treatment of cancer, has attracted the attention of publicly-traded Japanese firm Oncolys BioPharma, which has decided to invest $3 million in the St Louis-based start-up.
Both Unleash and Oncolys are in the development of oncolytic adenoviruses, which are specifically designed to spur the body’s immune system to attack cancer by invading the disease’s cells and enabling the body to recognise it, resulting in the death of the cancer and the virus.
